中华泌尿外科杂志
中華泌尿外科雜誌
중화비뇨외과잡지
CHINESE JOURNAL OF UROLOGY
2011年
6期
415-418
,共4页
伊庆同%龚旻%胡巍%田斌强%祝凤明%王天如%顾建军%陈楚红%郭建华%王华%陈长青
伊慶同%龔旻%鬍巍%田斌彊%祝鳳明%王天如%顧建軍%陳楚紅%郭建華%王華%陳長青
이경동%공민%호외%전빈강%축봉명%왕천여%고건군%진초홍%곽건화%왕화%진장청
索利那新%经尿道前列腺电切术%膀胱过度活动症
索利那新%經尿道前列腺電切術%膀胱過度活動癥
색리나신%경뇨도전렬선전절술%방광과도활동증
Solifenacin%Transurethal resection of the prostate%Overactive bladder
目的 探讨索利那新治疗经尿道前列腺电切(TURP)术后膀胱过度活动症(OAB)的疗效及安全性.方法 观察64例TURP术后OAB患者拔除尿管当天的排尿情况.根据OAB症状评分(OABSS),按OAB轻、中、重度进行配对后随机分为实验组和对照组,每组各32例.实验组:于拔除尿管后次日起口服索利那新(5 mg,1次/d)2周;对照组:无相关辅助治疗.比较2组拔除尿管后第7、14天的24 h尿急次数、排尿次数、夜尿次数、急迫性尿失禁次数、平均每次尿量、Qmax及OABSS评分.观察实验组治疗期间的不良事件.患者拔除尿管后随访8周.结果 实验组拔管后第7、14天的24 h尿急次数(2.0±1.2,1.1±0.9)、排尿次数(9.7±0.9,7.8±0.9)、夜尿次数(2.2±0.5,1.1±0.6)、急迫性尿失禁次数(0.8±0.7,0.5±0.5)、OABSS评分(7.3±3.1,4.0±2.8)均显著低于对照组的(2.9±1.7,2.2±1.4)、(10.5±1.1,9.6±0.9)、(2.9±0.5,1.8±0.5)、(1.6±1.0,1.1±0.8)、(8.1±3.1,7.6±3.3),2组比较差异均有统计学意义(P均＜0.01);实验组平均每次尿量[(183.0±38.3)、(203.2±51.1)ml]显著高于对照组[(172.6±35.3)、(178.4±38.2)ml],差异有统计学意义(P＜0.01).实验组在治疗期间不良反应总发生率为12.5%(4/32),但患者均可耐受,未发生严重不良事件.结论 索利那新治疗TURP术后OAB症状安全、有效,可于TURP术后早期应用.
目的 探討索利那新治療經尿道前列腺電切(TURP)術後膀胱過度活動癥(OAB)的療效及安全性.方法 觀察64例TURP術後OAB患者拔除尿管噹天的排尿情況.根據OAB癥狀評分(OABSS),按OAB輕、中、重度進行配對後隨機分為實驗組和對照組,每組各32例.實驗組:于拔除尿管後次日起口服索利那新(5 mg,1次/d)2週;對照組:無相關輔助治療.比較2組拔除尿管後第7、14天的24 h尿急次數、排尿次數、夜尿次數、急迫性尿失禁次數、平均每次尿量、Qmax及OABSS評分.觀察實驗組治療期間的不良事件.患者拔除尿管後隨訪8週.結果 實驗組拔管後第7、14天的24 h尿急次數(2.0±1.2,1.1±0.9)、排尿次數(9.7±0.9,7.8±0.9)、夜尿次數(2.2±0.5,1.1±0.6)、急迫性尿失禁次數(0.8±0.7,0.5±0.5)、OABSS評分(7.3±3.1,4.0±2.8)均顯著低于對照組的(2.9±1.7,2.2±1.4)、(10.5±1.1,9.6±0.9)、(2.9±0.5,1.8±0.5)、(1.6±1.0,1.1±0.8)、(8.1±3.1,7.6±3.3),2組比較差異均有統計學意義(P均＜0.01);實驗組平均每次尿量[(183.0±38.3)、(203.2±51.1)ml]顯著高于對照組[(172.6±35.3)、(178.4±38.2)ml],差異有統計學意義(P＜0.01).實驗組在治療期間不良反應總髮生率為12.5%(4/32),但患者均可耐受,未髮生嚴重不良事件.結論 索利那新治療TURP術後OAB癥狀安全、有效,可于TURP術後早期應用.
목적 탐토색리나신치료경뇨도전렬선전절(TURP)술후방광과도활동증(OAB)적료효급안전성.방법 관찰64례TURP술후OAB환자발제뇨관당천적배뇨정황.근거OAB증상평분(OABSS),안OAB경、중、중도진행배대후수궤분위실험조화대조조,매조각32례.실험조:우발제뇨관후차일기구복색리나신(5 mg,1차/d)2주;대조조:무상관보조치료.비교2조발제뇨관후제7、14천적24 h뇨급차수、배뇨차수、야뇨차수、급박성뇨실금차수、평균매차뇨량、Qmax급OABSS평분.관찰실험조치료기간적불량사건.환자발제뇨관후수방8주.결과 실험조발관후제7、14천적24 h뇨급차수(2.0±1.2,1.1±0.9)、배뇨차수(9.7±0.9,7.8±0.9)、야뇨차수(2.2±0.5,1.1±0.6)、급박성뇨실금차수(0.8±0.7,0.5±0.5)、OABSS평분(7.3±3.1,4.0±2.8)균현저저우대조조적(2.9±1.7,2.2±1.4)、(10.5±1.1,9.6±0.9)、(2.9±0.5,1.8±0.5)、(1.6±1.0,1.1±0.8)、(8.1±3.1,7.6±3.3),2조비교차이균유통계학의의(P균＜0.01);실험조평균매차뇨량[(183.0±38.3)、(203.2±51.1)ml]현저고우대조조[(172.6±35.3)、(178.4±38.2)ml],차이유통계학의의(P＜0.01).실험조재치료기간불량반응총발생솔위12.5%(4/32),단환자균가내수,미발생엄중불량사건.결론 색리나신치료TURP술후OAB증상안전、유효,가우TURP술후조기응용.
Objective To evaluate the efficacy and safety of solifenacin in the treatment of overactive bladder (OAB) syndrome in patients who have undergone transurethral resection of the prostate (TURP). Methods According to the Overactive Bladder Symptom Score (OABSS), 64 cases with OAB symptoms after TURP were randomly assigned into study and control groups with 32 cases in each group. Patients in the study group were treated with solifenacin (5 mg once daily) for a two week period beginning the first day after catheter removal. Patients in the control group were not treated with solifenacin. The mean urgency episodes, micturition episodes, nocturia, urge incontinence, volume voided per micturition, Qmax and OABSS scores were recorded on the 7th and the 14th day after catheter removal. Treatment-emergent adverse events with solifenacin in the study group were recorded and evaluated as well. All cases were followed-up for 8 weeks after catheter removal. Results There were statistically significant differences (P<0.01) in favor of the study group over the control group in the aspect of urgency, micturition episodes, nocturia, urge incontinence, volume voided per micturition and OABSS scores. The incidences of treatment related adverse events were 12.5% (4/32) in the study group with no serious adverse event observed. Conclusions Solifenacin is effective in the treatment of OAB syndrome after TURP and is well tolerated as well. Application of solifenacin should be recommended earlier after TURP.
